Dr. Swarup Kumar, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 133
Licensed in Connecticut since 2020, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CT license 066612 (first issued 2020; active) -
Internal Medicine Physician
CT license 066612 (first issued 2020; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- John Dempsey Hospital of the University of Connect Farmington, CT
Medical groups
- University of Connecticut Health Center (639 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 133
- Services billed
- 327
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 76 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 28 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 24 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 13 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Farmington, CT | 20 |
| Dexamethasone Other prescribers in Farmington, CT | 16 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Farmington, CT | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $9,427 in total to this clinician.
| Genzyme Corporation | $6,049 |
|---|---|
| Janssen Biotech, Inc. | $2,020 |
| Janssen Scientific Affairs, LLC | $1,320 |
| Kite Pharma, Inc. | $21.31 |
| Pfizer Inc. | $17.16 |
| Consulting Fee | $8,341 |
|---|---|
| Food and Beverage | $688 |
| Travel and Lodging | $381 |
| Education | $17.16 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 29, 2025 | Consulting Fee | $5,376 |
| Janssen Biotech, Inc. Oct 16, 2025 | Consulting Fee TALVEY; TECVAYLI · Oncology | $1,645 |
| Janssen Scientific Affairs, LLC Sep 18, 2025 | Consulting Fee DARZALEX · Oncology | $1,320 |
| Genzyme Corporation Oct 29, 2025 | Travel and Lodging travel to Philadelphia, PA | $274 |
| Genzyme Corporation Oct 29, 2025 | Travel and Lodging travel to Philadelphia, PA | $107 |
| Pfizer Inc. Mar 12, 2025 | Education ELREXFIO · ONCOLOGY · in-kind | $17.16 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $518,311 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who hav…
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who hav…
Janssen Research & Development, LLC - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED…
Celgene Corporation - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.